Drug Profile
BPX 701
Alternative Names: BPX701Latest Information Update: 05 Apr 2024
Price :
$50
*
At a glance
- Originator Leiden University Medical Center
- Developer Bellicum Pharmaceuticals; Leiden University Medical Center
- Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; Immunostimulants; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Malignant melanoma; Myelodysplastic syndromes; Neuroblastoma; Sarcoma; Uveal melanoma
Most Recent Events
- 23 Feb 2024 Discontinued - Phase-I for Acute myeloid leukaemia (Recurrent, Treatment-resistant) in USA (IV) before February 2024 as Bellicum Pharmaceuticals has winded down its business and no longer active
- 23 Feb 2024 Discontinued - Phase-I for Myelodysplastic syndromes (Recurrent, Treatment-resistant) in USA (IV) before February 2024 as Bellicum Pharmaceuticals has winded down its business and no longer active
- 24 Jul 2023 Discontinued - Preclinical for Malignant melanoma in USA (IV)